===========================================================================
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
Albany Molecular Research, Inc.
---------------------------------------
(Name of Issuer)
COMMON STOCK, $.01 PAR VALUE
---------------------------------------------------------------------------
(Title of Class of Securities)
012423 10 9
-----------------
(CUSIP Number)
December 15, 1999
-------------------------------------------------------
(Date of Event Which Requires Filing of This Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
[ ] Rule 13d-1(b)
[ ] Rule 13d-1(c)
[ x ] Rule 13d-1(d)
===========================================================================
Page 1 of 9
Exhibit Index is located at page 8
<PAGE> 2
CUSIP No. 012423 10 9
- ---------------------------------------------------------------------------
1) Name of Reporting Person and its Aventis Pharmaceuticals Inc.
I.R.S. Identification Number 44-0565557
- ---------------------------------------------------------------------------
2) Check the Appropriate Box if (a)[ ]
a Member of a Group (b)[ x ]
- ---------------------------------------------------------------------------
3) SEC Use Only
- ---------------------------------------------------------------------------
4) Citizenship or Place of Organization Delaware
- ---------------------------------------------------------------------------
5) Sole Voting Power 1,627,231
Number of __________________________________________________
Shares
Beneficially 6) Shared Voting Power 0
Owned by _________________________________________________________
Each
Reporting 7) Sole Dispositive Power 1,627,231
Person With ______________________________________________________________
8) Shared Dispositive Power 0
- ---------------------------------------------------------------------------
9) Aggregate Amount Beneficially Owned 1,627,231
by Each Reporting Person
- ---------------------------------------------------------------------------
10) Check Box If the Aggregate Amount [ ]
in Row (9) Excludes Certain Shares
- ---------------------------------------------------------------------------
11) Percent of Class Represented 11.2%
by Amount in Row (9)
- ---------------------------------------------------------------------------
12) Type of Reporting Person CO
- ---------------------------------------------------------------------------
<PAGE> 3
CUSIP No. 012423 10 9 13G
- ---------------------------------------------------------------------------
1) Name of Reporting Person and its HMR Pharma, Inc.
I.R.S. Identification Number 43-1769328
- ---------------------------------------------------------------------------
2) Check the Appropriate Box if (a)[ ]
a Member of a Group (b)[ x ]
- ---------------------------------------------------------------------------
3) SEC Use Only
- ---------------------------------------------------------------------------
4) Citizenship or Place of Organization Delaware
- ---------------------------------------------------------------------------
5) Sole Voting Power 1,627,231
Number of ____________________________________________________
Shares
Beneficially 6) Shared Voting Power 0
Owned by _________________________________________________________
Each
Reporting 7) Sole Dispositive Power 1,627,231
Person With ______________________________________________________________
8) Shared Dispositive Power 0
- ---------------------------------------------------------------------------
9) Aggregate Amount Beneficially Owned 1,627,231
by Each Reporting Person
- ---------------------------------------------------------------------------
10) Check Box If the Aggregate Amount [ ]
in Row (9) Excludes Certain Shares
- ---------------------------------------------------------------------------
11) Percent of Class Represented 11.2%
by Amount in Row (9)
- ---------------------------------------------------------------------------
12) Type of Reporting Person CO
- ---------------------------------------------------------------------------
<PAGE> 4
CUSIP No. 012423 10 9 13G
This Statement on Schedule 13G (the "Schedule 13G") with respect to the
Common Stock of Albany Molecular Research, Inc. (the "Issuer"), is filed jointly
by Aventis Pharmaceuticals Inc., a Delaware corporation ("API"), and HMR Pharma,
Inc., a Delaware corporation ("Pharma"), to reflect the ownership by API (and
deemed beneficial ownership by Pharma) of Common Stock of Albany Molecular
Research, Inc. API acquired its interest in Albany Molecular Research before the
issuer had a class of securities registered pursuant to Section 12 of the
Securities Exchange Act of 1934, and thus is not required to file this Statement
until 45 days after the end of calendar year 1999 pursuant to Rule 13d-1(d).
This Schedule is being filed at this time to reflect a change in the ultimate
parent of API and Pharma, which occurred December 15, 1999.
ITEM 1(a). NAME OF ISSUER:
- -------------- - -----------------------
Albany Molecular Research, Inc.
ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
- -------------- -------------------------------------------------------------
21 Corporate Circle
Albany, NY 12203-5154
ITEM 2(a). NAME OF PERSON FILING:
- ------------- -------------------------------------
Aventis Pharmaceuticals Inc.
HMR Pharma, Inc.
ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
- ------------- -------------------------------------------------------------
Aventis Pharmaceuticals Inc.
10236 Marion Park Drive
Kansas City, Missouri 64137-1405
HMR Pharma, Inc.
10236 Marion Park Drive
Kansas City, Missouri 64137-1405
ITEM 2(c). CITIZENSHIP:
- -------------- ------------------
Delaware As To Both Aventis Pharmaceuticals Inc. and
HMR Pharma, Inc.
ITEM 2(d). TITLE OF CLASS OF SECURITIES:
- -------------- ---------------------------------------------
Common Stock, $.01 Par Value
<PAGE> 5
CUSIP No. 012423 10 9 13G
ITEM 2(e): CUSIP NUMBER:
- -------------- -----------------------
012423 10 9
ITEM 3: IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(b) OR
13D-2(b):
- ---------- -------------------------------------------------------------
Not Applicable
ITEM 4. OWNERSHIP:
- ---------- -------------------
(a): AMOUNT BENEFICIALLY OWNED:
As Of 11/10/99 1,627,231 Shares Of Common Stock.
(b): PERCENT OF CLASS:
11.2%
(c): NUMBER OF SHARES AS TO WHICH SUCH PERSON HAS:
(i) Sole power to vote or to direct the vote: 1,627,231
(ii) Shared power to vote or to direct the vote: 0
(iii) Sole power to dispose or to direct the disposition of: 1,627,231
(iv) Shared power to dispose or to direct the disposition of: 0
ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
- ---------- --------------------------------------------------------------
Not Applicable
<PAGE> 6
CUSIP No. 012423 10 9 13G
ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
- ----------- ----------------------------------------------------------------
Not Applicable
ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH
- ---------- ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING
COMPANY
- -------------------------------------------------------------------------------
Not Applicable
ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
- ---------- -------------------------------------------------------------
Not Applicable
ITEM 9. NOTICE OF DISSOLUTION OF GROUP.
- ---------- ---------------------------------------------------
Not Applicable
ITEM 10. CERTIFICATION.
- ----------- -----------------------
Not Applicable
<PAGE> 7
CUSIP No. 012423 10 9 13G
SIGNATURES
-------------------
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
AVENTIS PHARMACEUTICALS INC.
Date: December 22, 1999 By: /s/ Rebecca R. Tilden
- --------------------------------- --------------------------
Rebecca R. Tilden
Vice President and Secretary
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
HMR PHARMA, INC.
Date: December 22, 1999 By: /s/ Rebecca R. Tilden
--------------------------
Rebecca R. Tilden
Vice President and Assistant Secretary
<PAGE> 8
CUSIP No. 012423 10 9 13G
EXHIBIT INDEX
Exhibit No. Description Page No.
- -------------- ------------ ---------
99.A Agreement to File Jointly dated December 9
22, 1999, by and between Aventis
Pharmaceuticals Inc. and HMR Pharma, Inc.
<PAGE> 9
CUSIP No. 012423 10 9 13G
EXHIBIT 99.A
AGREEMENT TO FILE JOINTLY
We, the undersigned, hereby express our agreement that the attached
Schedule 13G is filed on behalf of each of us.
AVENTIS PHARMACEUTICALS INC.
Date: December 22, 1999 By: /s/ Rebecca R. Tilden
- --------------------------------- --------------------------
Rebecca R. Tilden
Vice President and Secretary
HMR PHARMA, INC.
Date: December 22, 1999 By: /s/ Rebecca R. Tilden
--------------------------
Rebecca R. Tilden
Vice President and Assistant Secretary
